25% decline in bariatric surgeries due to increased GLP-1 drug use for obesity management.

The use of GLP-1 drugs for obesity management has surged, leading to a 25% decline in bariatric surgeries in the U.S. These medications, effective in appetite regulation and blood sugar control, offer a non-invasive alternative to surgery. Patients increasingly prefer GLP-1 drugs for their lower risks and side effects. This trend signifies a notable shift in obesity treatment approaches within the healthcare industry.

October 25, 2024
12 Articles

Further Reading